Drug Safety Advocates Want Bioequivalence Data To Be Made Public

A group of drug safety advocates are pushing for FDA to make its bioequivalence data available so that physicians, pharmacists, researchers and buyers can see how the agency makes such determinations, which they say in some cases can lead to a large difference between the amount of active ingredient an innovator product and a generic drug version deliver to a patient, according to a working paper the advocates unveiled Wednesday (March 18). The advocates also touch upon challenges that FDA...